Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Morphine
Drug ID BADD_D01498
Description Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805.[A176035] It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse.[A176050] Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941.[L12114]
Indications and Usage For the relief and treatment of severe pain.
Marketing Status Prescription; Discontinued
ATC Code N02AA01
DrugBank ID DB00295
KEGG ID D08233
MeSH ID D009020
PubChem ID 5288826
TTD Drug ID D0WE3O
NDC Product Code 42799-217
Synonyms Morphine | Morphia | Morphine Chloride | Chloride, Morphine | Morphine Sulfate | Sulfate, Morphine | SDZ 202-250 | SDZ 202 250 | SDZ 202250 | SDZ202-250 | SDZ202 250 | SDZ202250 | Morphine Sulfate (2:1), Pentahydrate | MS Contin | Contin, MS | Oramorph SR | Duramorph | Morphine Sulfate (2:1), Anhydrous
Chemical Information
Molecular Formula C17H19NO3
CAS Registry Number 57-27-2
SMILES CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cardiac arrhythmiasMu-type opioid receptorP35372T477688383026; 1528399; 1654493; 8490741; 1279757; 7521466
Cardiac arrhythmiasMu-type opioid receptorP35372T4776825806604
HyperpathiaTranscription factor JunP05412T6908525806604
HyperpathiaMu-type opioid receptorP35372T4776825806604
HyperpathiaMitogen-activated protein kinase 8P45983T4009725806604
HyperpathiaProtein kinase C alpha typeP17252T1280825806604
HyperpathiaMu-type opioid receptorP35372T477688383026; 1528399; 1654493; 8490741; 1279757; 7521466
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Paraparesis17.01.04.0060.001171%Not Available
Paraplegia17.01.04.0070.000367%Not Available
Pericardial effusion02.06.01.002--
Pericarditis02.06.02.0010.001406%
Peripheral sensory neuropathy17.09.03.0050.000469%
Peroneal nerve palsy17.09.02.003--Not Available
Persistent foetal circulation18.04.07.001; 03.07.01.002; 02.08.02.001; 24.03.03.0040.000122%Not Available
Personality change17.02.05.019; 19.05.01.0060.000703%
Pharyngeal oedema23.04.01.016; 22.04.05.003; 10.01.05.0160.001874%Not Available
Phlebitis24.05.03.001; 12.02.01.0020.000469%
Photophobia17.17.02.006; 06.01.01.004--
Piloerection23.02.06.005--Not Available
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pneumonia aspiration22.01.01.0050.001039%Not Available
Pneumothorax22.05.02.003--
Polyuria20.02.03.002--Not Available
Post herpetic neuralgia11.07.01.010; 17.02.07.014--Not Available
Premature baby18.04.02.001--Not Available
Premature delivery18.07.01.006--
Presyncope24.06.02.010; 17.02.05.009; 02.01.02.007--
Prolonged labour18.07.01.001--Not Available
Prostate cancer metastatic21.04.02.004; 16.25.01.0020.000122%Not Available
Pruritus23.03.12.0010.078256%
Psychomotor hyperactivity19.11.02.003; 17.01.02.011--Not Available
Pulmonary congestion24.03.08.001; 22.01.03.002; 02.05.02.0020.000244%Not Available
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary haemorrhage24.07.01.016; 22.02.04.003--
Pulmonary hypertension24.08.03.002; 22.06.01.001--
Pulmonary oedema22.01.03.003; 02.05.02.0030.001467%
Pulse absent13.14.04.0050.000937%Not Available
The 12th Page    First    Pre   12 13 14 15 16    Next   Last    Total 21 Pages